Julie Lin
Senior Vice President, Clinical Development & Drug Safety/ Pharmacovigilance Travere Therapeutics
Seminars
Thursday 20th August 2026
Implementing Master Protocols and Bayesian Clinical Trial Designs with Goal of Accelerating Clinical Development in Rare Kidney Diseases
8:30 am
- Leveraging Learnings from Oncology: Applying Basket, Umbrella, and Platform Trial Designs to Renal Disease
- Implementing Bayesian Clinical Trial Designs: Interpreting Recent Regulatory Guidance and Real-World Examples
Thursday 20th August 2026
Fireside Discussion: From Asset Evaluation to Integration: How Strategic Dealmaking Accelerates Rare Kidney Disease Drug Development
3:30 pm
- Evaluating rare kidney disease assets: What factors beyond clinical stage influence portfolio fit and investment decisions
- Cross-functional diligence in action: How business development, clinical, regulatory, and safety teams collaborate to assess opportunities under tight timelines
- From deal to development: Best practices for integrating newly acquired programs and maintaining momentum in clinical trials for diseases such as IgA Nephropathy and Focal Segmental Glomerulosclerosis
